Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial.

@article{Nabhan2009ErlotinibHM,
  title={Erlotinib has moderate single-agent activity in chemotherapy-na{\"i}ve castration-resistant prostate cancer: final results of a phase II trial.},
  author={Chadi Nabhan and Timothy M. Lestingi and Angel G Galvez and Kathy Tolzien and Susan K Kelby and Dean Tsarwhas and Steven M Newman and Jacob David Bitran},
  journal={Urology},
  year={2009},
  volume={74 3},
  pages={665-71}
}
OBJECTIVES To investigate the efficacy and toxicity of single-agent erlotinib in chemotherapy-naive castration-resistant prostate cancer. METHODS Eligible patients received erlotinib at 150 mg daily until disease progression. Toxicity was assessed every 2 weeks and responses every 8 weeks. Primary end point was assessing the overall clinical benefit measured as the sum of stable disease, partial response, and complete response. Secondary end points included time to disease progression… CONTINUE READING